Ligand validation:4TNB

SGV: SANGIVAMYCIN

SGV is a Ligand Of Interest in 4TNB designated by the RCSB

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
4TNB_SGV_A_601	83%	4%	0.096	0.956	2.33	3.46	7	6	0	0	100%	1
6PJX_SGV_A_601	79%	3%	0.131	0.976	2.17	3.92	7	7	0	0	100%	1
8OV2_SGV_A_7222	83%	3%	0.088	0.947	4.05	2.27	12	7	0	0	100%	1
6C9N_SGV_A_401	83%	17%	0.112	0.97	2.04	1.59	5	4	0	0	100%	1
5AQZ_SGV_A_1389	78%	55%	0.085	0.926	0.94	0.8	2	1	0	0	100%	1
9EMV_SGV_A_7201	63%	2%	0.113	0.906	4.37	2.65	11	10	1	0	100%	0.36

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.